54
Participants
Start Date
July 12, 2021
Primary Completion Date
September 30, 2024
Study Completion Date
September 30, 2039
FT819
Experimental Interventional Therapy
Cyclophosphamide
Lympho-conditioning agent
Fludarabine
Lympho-conditioning agent
IL-2
Biologic response modifier
Bendamustine
Lympho-conditioning agent
Memorial Sloan Kettering Cancer Center, New York
Mayo Florida, Jacksonville
University of Alabama at Birmingham, Birmingham
Norton Cancer Institute, St. Matthews Campus, Louisville
University of Iowa, Iowa City
University of Wisconsin-Madison, Madison
Mayo Minnesota, Rochester
The University of Kansas Cancer Center, Westwood
University of Nebraska Medical Center, Omaha
MD Anderson Cancer Center, Houston
Mayo Arizona, Phoenix
UCLA Ronald Reagan Medical Center, Los Angeles
Scripps Green Hospital, La Jolla
Stanford Cancer Institute, Palo Alto
UC Davis, Davis
Oregon Health & Sciences University, Portland
Hackensack University Medical Center, Hackensack
Lead Sponsor
Fate Therapeutics
INDUSTRY